Cited by 466CAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Open access

Hinrichs, Christian S., Rosenberg, Steven A.·2014·Immunological Reviews

DOI 10.1111/imr.12132PMC PMC3920180

Open this paper in CoChat — free account

Abstract

Summary: Adoptive T‐cell therapy (ACT) is a potent and flexible cancer treatment modality that can induce complete, durable regression of certain human malignancies. Long‐term follow‐up of patients receiving tumor‐infiltrating lymphocytes (TIL s) for metastatic melanoma reveals a substantial subset that experienced complete, lasting tumor regression – and may be cured. Increasing evidence points to mutated gene products as the primary immunological targets of TIL s from melanomas. Recent technological advances permit rapid identification of the neoepitopes resulting from these somatic gene mutations and of T cells with reactivity against these targets. Isolation and adoptive transfer of these T cells may improve TIL therapy for melanoma and permit its broader application to non‐melanoma tumors. Extension of ACT to other malignancies may also be possible through antigen receptor gene engineering. Tumor regression has been observed following transfer of T cells engineered to express chimeric antigen receptors against CD 19 in B‐cell malignancies or a T‐cell receptor against NY‐ESO‐1 in synovial cell sarcoma and melanoma. Herein, we review recent clinical trials of TIL s and antigen receptor gene therapy for advanced cancers. We discuss lessons from this experience and consider how they might be applied to realize the full curative potential of ACT.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/imr.12132

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citation
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citation

Show all 137 references

Sorted by citations

Items 301–400 of 465

Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement
Kim, D., Lee, G., Cho, H., & Bae, S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.737504 · Cited by 12
Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target
Bose, M. (2023) · International Journal of Translational Medicine · doi:10.3390/ijtm3030024 · Cited by 12
Generation of antigen-specific mature T cells from RAG1−/−RAG2−/−B2M−/− stem cells by engineering their microenvironment
Chang, P. C., Yuan, X., Zampieri, A., Towns, C., Yoo, S. P., Engstrom, C., Tsai, S. C., Robles, C. R., Zhu, Y., Lopez, S., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01146-7 · Cited by 12
Producing proT cells to promote immunotherapies
Singh, J., & Zúñiga‐Pflücker, J. C. (2018) · International Immunology · doi:10.1093/intimm/dxy051 · Cited by 12
Natural killer cell-based strategies for immunotherapy of cancer
Vaněk, O., Kalousková, B., Abreu, C., Nejadebrahim, S., & Skořepa, O. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.02.001 · Cited by 11
Neoantigen vaccine and neoantigen‐specific cell adoptive transfer therapy in solid tumors: Challenges and future directions
Shen, Y., Yu, L., Xu, X., Yu, S., & Yu, Z. (2022) · Cancer Innovation · doi:10.1002/cai2.26 · Cited by 12
The Current Landscape of Early Drug Development for Patients with Sarcoma in the Immunotherapy Era
Sebio, A., Wilky, B. A., Keedy, V. L., & Jones, R. L. (2018) · Future Oncology · doi:10.2217/fon-2017-0565 · Cited by 11
Ecto-5′-Nucleotidase (CD73) Regulates the Survival of CD8+ T Cells
Rosemblatt, M. V., Parra-Tello, B., Briceño, P., Rivas-Yáñez, E., Tüçer, S., Saavedra-Almarza, J., Hörmann, P., Martínez, B. A., Lladser, Á., Rosemblatt, M. S., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.647058 · Cited by 11
Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal
Morris, V. K., & Eng, C. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7040 · Cited by 11
Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies
Zhu, H., & Liu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666340 · Cited by 12
Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells
Vasileiou, M., Diamantoudis, S. C., Tsianava, C., & Nguyen, N. P. (2024) · Current Oncology · doi:10.3390/curroncol31060232 · Cited by 10
Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects
Hegde, M. M., Sandbhor, P., Aishwarya, J., Gota, V., & Goda, J. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168454 · Cited by 11
Use of Magnetotactic Bacteria as an MRI Contrast Agent for In Vivo Tracking of Adoptively Transferred Immune Cells
Nuschke, A., Sobey-Skelton, C., Dawod, B., Kelly, B., Tremblay, M., Davis, C., Rioux, J., & Brewer, K. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01849-y · Cited by 10
Harnessing the immune system for the treatment of melanoma: current status and future prospects
Guennoun, A., Sidahmed, H., Maccalli, C., Seliger, B., Marincola, F. M., & Bedognetti, D. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1176529 · Cited by 10
Clinical Decision Making
Goodwin, C. R., Abu-Bonsrah, N. A., Bilsky, M. H., Reynolds, J., Rhines, L. D., Laufer, I., Disch, A. C., Bozsódi, Á., PATEL, S. R., Gokaslan, Z. L., et al. (2016) · Spine · doi:10.1097/brs.0000000000001836 · Cited by 10
More Haste, Less Speed: Could Public–Private Partnerships Advance Cellular Immunotherapies?
Bubela, T. M., Bonter, K., Lachance, S., Delisle, J., & Gold, E. R. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00134 · Cited by 10
Opportunities and Challenges for the Cellular Immunotherapy Sector: A Global Landscape of Clinical Trials
Bonter, K., Breckenridge, Z. M., Lachance, S., Delisle, J., & Bubela, T. M. (2017) · Regenerative Medicine · doi:10.2217/rme-2017-0031 · Cited by 10
Functional genomics: paving the way for more successful cancer immunotherapy
Ajina, R., Zamalin, D., & Weiner, L. M. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely017 · Cited by 11
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells
Alrifai, D., Sarker, D., & Maher, J. F. (2015) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1100204 · Cited by 10
Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models
Zheng, Y., Hu, B., Xie, S., Chen, X., Hu, Y., Chen, W., Li, S., & Hu, B. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.01.008 · Cited by 10
Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy
Furusawa, A., Reiser, J., Sadashivaiah, K., Simpson, H. M., & Banerjee, A. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000206 · Cited by 10
Elucidating DNA Damage-Dependent Immune System Activation
Deligianni, E., Papanikolaou, C., Terpos, E., & Souliotis, V. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125849 · Cited by 10
The modulation of Dicer regulates tumor immunogenicity in melanoma
Hoffend, N. C., Magner, W. J., & Tomasi, T. B. (2016) · Oncotarget · doi:10.18632/oncotarget.10273 · Cited by 9
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy
Jazirehi, A. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111726 · Cited by 9
The future in an RNA molecule: from mRNA vaccines to therapeutics – An interview with Drew Weissman
Ruffell, D. (2021) · FEBS Letters · doi:10.1002/1873-3468.14190 · Cited by 9
Broadening the repertoire of melanoma-associated T-cell epitopes
Frøsig, T. M., Lyngaa, R., Met, Ö., Larsen, S. K., Donia, M., Svane, I. M., Straten, P. T., & Hadrup, S. R. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1664-x · Cited by 9
Genetically modified human CD 4+ T cells can be evaluated in vivo without lethal graft‐versus‐host disease
Ali, R., Babad, J., Follenzi, A., Gebe, J. A., Brehm, M. A., Nepom, G. T., Shultz, L. D., Greiner, D. L., & DiLorenzo, T. P. (2016) · Immunology · doi:10.1111/imm.12613 · Cited by 9
State of the Art Treatment and Surveillance Imaging of Glioblastomas
Margiewicz, S., Cordova, C., Chi, A. S., & Jain, R. (2017) · Seminars in Roentgenology · doi:10.1053/j.ro.2017.11.003 · Cited by 9
A photosensitizer delivered by bispecific antibody redirected T lymphocytes enhances cytotoxicity against EpCAM-expressing carcinoma cells upon light irradiation
Blaudszun, A., Moldenhauer, G., Schneider, M., & Philippi, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.10.025 · Cited by 9
Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy
Rasool, S., Rutella, S., Ferrone, S., & Maccalli, C. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-16624-3_9 · Cited by 9
A Comprehensive Survey of Immune Cytolytic Activity-Associated Gene Co-Expression Networks across 17 Tumor and Normal Tissue Types
Tian, T., Wan, J., Han, Y., Liu, H., Gao, F., Pan, Y., Song, Q., & Wei, Z. (2018) · Cancers · doi:10.3390/cancers10090307 · Cited by 8
IL7-Fc Enhances the Efficacy of Adoptive T Cell Therapy under Lymphopenic Conditions in a Murine Melanoma Model
Yu, E. M., Cho, E., Singh, R., Kim, S.-H., Han, C., Han, S., Lee, D. G., Kim, Y. H., Kwon, B. S., & Choi, B. K. (2021) · Cells · doi:10.3390/cells10082018 · Cited by 8
Tumor Antigens beyond the Human Exome
Emilius, L., Bremm, F., Binder, A. K., Schaft, N., & Dörrie, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094673 · Cited by 9
An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy
Westwood, J. A., Ellis, S. L., Danne, J., Johnson, C., Oorschot, V. M. J., Ramm, G., Tscharke, D. C., Davenport, A. J., Whisstock, J. C., Darcy, P. K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23215 · Cited by 8
Breast cancer immunotherapy: a comprehensive review
Keshavarz, S., Wall, J. R., Keshavarz, S., Vojoudi, E., & Jafari-Shakib, R. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01177-z · Cited by 8
Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
Aderonke, A. B., Ibrahim, R. B., & Huang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184624 · Cited by 8
Survival correlation of immune response in human cancers
Liu, Y. (2019) · Oncotarget · doi:10.18632/oncotarget.27360 · Cited by 8
Targeting HPV in gynaecological cancers – Current status, ongoing challenges and future directions
Crusz, S. M., El-Shakankery, K. H., & Miller, R. E. (2020) · Women s Health · doi:10.1177/1745506520961709 · Cited by 8
Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells
Wang, H., Zhu, T., Yang, K., Xu, C., Zhang, Z., Liu, G., & Ren, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1702219 · Cited by 8
Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review
Taylor, S., Law, K., Coomber-Moore, J., Davies, M., Thistlethwaite, F. C., Calvert, M., Aiyegbusi, O. L., & Yorke, J. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02337-8 · Cited by 7
Therapeutics incorporating blood constituents
Charoenphol, P., Oswalt, K., & Bishop, C. J. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.03.046 · Cited by 8
Natural killer cels in immunotherapy for cancer
Боробова, Е. А., & Жеравин, А. А. (2019) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2018-17-6-97-104 · Cited by 7
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
Ashi, M. O., Mami‐Chouaib, F., & Corgnac, S. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00111 · Cited by 7
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials
Cabanski, C. R., Yang, E., Stewart, M. D., Allen, J. D., Connolly, J. E., Dugan, U., Greenberg, P. D., Mackall, C. L., June, C. H., Marson, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011301 · Cited by 6
Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
Quintarelli, C., Camera, A., Ciccone, R., Alessi, I., Bufalo, F. D., Carai, A., Baldo, G. D., Mastronuzzi, A., & Angelis, B. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634031 · Cited by 6
Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
Luo, H., Liu, G., Jian, D., Liang, D., Li, X., Zhong, L., Yang, B. Y., Jiang, J. H., Wang, D., Li, M., et al. (2022) · Journal of Immunology Research · doi:10.1155/2022/9962397 · Cited by 6
The synergistic antitumor effect of arsenic trioxide combined with cytotoxic T cells in pulmonary metastasis model of colon cancer
Wang, L., Liang, W., Peng, N., Hu, X., Xu, Y., & Liu, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.22757 · Cited by 6
High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells
Kang, S., Li, Y., Bao, Y., & Li, Y. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0677-1 · Cited by 6
Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors
Ward-Kavanagh, L. K., Kokolus, K. M., Cooper, T. K., Lukacher, A. E., & Schell, T. D. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2115-2 · Cited by 6
Immunoproteasomes and immunotherapy—a smoking gun for lung cancer?
Spits, M., & Neefjes, J. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.05.21 · Cited by 6
The challenges and progress of CAR-T cell therapy in the treatment of solid tumors
Cui, K., He, W., Huang, N., Zhu, S., Jiang, D., Yang, W., Zeng, Y., Farooq, M. A., & Xu, G. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05329-5 · Cited by 5
Synthetic immunity to break down the bottleneck of cancer immunotherapy
Chen, Z., Ma, F., Huang, H., & He, C. (2015) · 中国科学通报：英文版 · doi:10.1007/s11434-015-0794-z · Cited by 5
Tumor Infiltrating Cytotoxic CD8 T‑Cells Predict Clinical Outcome of Neuroblastoma in Children
Rahbar, M., Mehrazma, M., & Karimian, M. (2018) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_78_17 · Cited by 5
Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients
Zhang, W., Liu, K., Ye, B., Hu, G., Zhao, K., Ren, Y., & Liang, W. (2017) · Oncology Letters · doi:10.3892/ol.2017.6635 · Cited by 5
Rare tumors: a blue ocean of investigation
Wang, S., Ma, P., Jiang, N., Jiang, Y., Yu, Y., Fang, Y., Miao, H., Huang, H., Tang, Q., Cui, D., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-0984-z · Cited by 5
Emerging Nanomaterials for Cancer Therapy
Kumar, S., Kumari, P., & Singh, R. (2019) · Springer eBooks · doi:10.1007/978-981-13-8954-2_2 · Cited by 5
Overview of Current Cancer Immunotherapy
Yamaguchi, Y. (2016) · Springer eBooks · doi:10.1007/978-4-431-55031-0_1 · Cited by 5
Novel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails
Liu, B., Shen, J., Wu, Y., Wong, C. F., Hei, T. Y., Li, J. W.-T., Hummel, S. N., Jin, G., Petrucci, N. R., Wang, D. M., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.06.025 · Cited by 4
Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task
June, C. H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0075 · Cited by 4
The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease.
Johnson, B., & Eng, C. (2017) · PubMed · Cited by 4
Induction of γδT cells from HSC‐enriched BMCs co‐cultured with iPSC‐derived thymic epithelial cells
Hosaka, N., Kanda, S., Shimono, T., & Nishiyama, T. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16993 · Cited by 4
Modeling and Viewing T Cell Receptors Using TCRmodel and TCR3d
Gowthaman, R., & Pierce, B. G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0327-7_14 · Cited by 4
A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells
Chen, Y.-J., Chen, M. J., Cheng, T., Tsai, Y.-S., Wang, C.-H., Chen, C.-Y., Wu, T.-Y., Tzou, S.-C., Wang, K., Cheng, J., et al. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00929-z · Cited by 4
Mutant Epitopes in Cancer
Rao, M., Zhenjiang, L., Meng, Q., Sinclair, G., Dodoo, E., & Maeurer, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_4 · Cited by 4
Magneto-Thermal Effect in Mn0.25Fe2.75O4-PEG Nanoparticles and Their Potential as Hyperthermia Therapy
Sunaryono, S., Saputra, K., Hidayat, A., Yogihati, C. I., Wicaksono, S. T., Hidayat, N., Hidayat, S., & Soontaranon, S. (2019) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/515/1/012008 · Cited by 4
Current strategies for adoptive immunotherapy for cancer: ”Off-the-shelf” immune cells
Ngo, H. T., Manh, H. L. V., Dang, V. T., Nguyen, N. H.-T., Thanh, B. V., & Pham, P. V. (2020) · Biomedical Research and Therapy · doi:10.15419/bmrat.v7i12.655 · Cited by 4
Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies
Matsueda, S., Chodon, T., & Koya, R. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_10 · Cited by 4
Lymphatic dissemination of HPV-positive oropharyngeal squamous cell carcinoma: underlying mechanisms and treatment innovations
Li, X., Qiu, H., & Wu, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601572 · Cited by 3
Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy
Fahimeh Baghaei, A., Hemmat, Z., Taherkhani, A., Setareh Shojaei, A., & Teimoori, A. (2025) · Journal of Immunology Research · doi:10.1155/jimr/9126083 · Cited by 3
Engineering a Novel T‐Cell Epitope‐Based Vaccine Targeting PRAME in Cancer Immunotherapy
Bayat, Z., Majidi, Z., Taherkhani, A., & Samie, L. (2025) · Peptide Science · doi:10.1002/pep2.24393 · Cited by 3
Cancer Immunotherapy by Checkpoint Blockade
Minato, N., & Honjo, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00029-1 · Cited by 3
Cancer T-cell therapy: building the foundation for a cure
Kamb, A., & Go, W. Y. (2020) · F1000Research · doi:10.12688/f1000research.27217.1 · Cited by 3
Neo-Splicetopes in Tumor Therapy: A Lost Case?
Kloetzel, P. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849863 · Cited by 3
Adoptive T Cell Transfer
Shaffer, D. R., Cruz, C. C., & Rooney, C. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_3 · Cited by 3
Biomolecule Conjugation Strategy for HAGM Cryogels to Create 3D Immune Niches that Induce Multifunctional T Cells
Schluck, M., Weiden, J., Hammink, R., Weiss, L., Quiroz, M. E. V., Pfirrmann, M., Guinovart, L. J., van der Steen, V., Archidi, C., Minall, L., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00134 · Cited by 2
Regulatory T cells and peripheral immune tolerance: key mechanisms and therapeutic strategies for cardiovascular diseases
Lin, M., Li, W. X., Wu, Y., Li, M., Li, Y., & Zhao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1776040 · Cited by 2
Cancer Immunotherapy and Immunonutrition
Wang, F. (2017) · MOJ Anatomy & Physiology · doi:10.15406/mojap.2017.03.00104 · Cited by 2
Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack
Norde, W. J., Hobo, W. A., & Dolstra, H. (2015) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-17807-3_2 · Cited by 2
Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?
Cogdill, A. P., Prieto, P. A., Reuben, A., & Wargo, J. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2493 · Cited by 2
Improved Targeting of Therapeutics by Nanocarrier-Based Delivery in Cancer Immunotherapy and Their Future Perspectives
Dhara, A., Majumder, S., Pahari, S., & Kar, D. (2023) · BioNanoScience · doi:10.1007/s12668-023-01065-6 · Cited by 2
[Corrigendum] Clinical and biological effects of tumor associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients
Zhang, W., Liu, K., Ye, B., Hu, G., Zhao, K., Ren, Y., & Liang, W. (2018) · Oncology Letters · doi:10.3892/ol.2018.8537 · Cited by 2
Harnessing the Immune System to Target Cancer Cells
Maccalli, C. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-16624-3_6 · Cited by 1
A detailed review of immunotherapeutics with a special emphasis on hybridoma technology
Vaghela, A. R., & Ganatra, T. H. (2024) · American Journal of Biopharmacy and Pharmaceutical Sciences · doi:10.25259/ajbps_13_2023 · Cited by 1
Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical barriers
Freitas, R., Peixoto, A., Santos, L. L., & Ferreira, J. A. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189327 · Cited by 1
Genetically engineered T cell and tumour-infiltrating lymphocyte therapies
Laubli, H. P., & Holbro, A. (2025) · Swiss Medical Weekly · doi:10.57187/s.4279 · Cited by 1
The role of miR-3188-mediated transcriptional activation of IL-7Rα in tumor immunotherapy research
Wan, D., Liang, X., Liang, F., Zhu, M., Zhang, C., & Zhang, S. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.12.007 · Cited by 1
S1P in Tumor Microenvironment and Modulation of Anti-Tumor-Directed T-Cell Responses
António, P. A., Lérias, J. R., Gorgulho, C. M., Balan, K., Balan, V., & Maeurer, M. J. (2026) · Cells · doi:10.3390/cells15100909 · Cited by 1
Multiplexed immunohistochemical analysis of the immune microenvironment of biliary tract cancers pre- & post-neoadjuvant chemotherapy: case series
Dharmapuri, S., Cabal, R., Aktürk, G., Ioannou, G., Ozbey, S., Paulsen, J. D., Raina, S., Ang, C., Sarpel, U., Sung, M. W., et al. (2024) · Annals of Translational Medicine · doi:10.21037/atm-23-1928 · Cited by 1
Effective Cancer Immunotherapy – Are We There Yet?
Williams, J. L., & Kashat, E. (2015) · American Society for Clinical Laboratory Science · doi:10.29074/ascls.28.1.46 · Cited by 1
Identification and assessment of TCR-T cells targeting an epitope conserved in SARS-CoV-2 variants for the treatment of COVID-19
Ma, Y., Liu, F., Li, B., Peng, K., Zhou, H., Xu, Y., Qiao, D., Deng, L., Tian, G., Nielsen, M., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109283 · Cited by 1
Appraising γδ T cell exhaustion and differentiation in the context of synthetic engineering for cancer immunotherapy
Anderson, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21766-1.00009-6 · Cited by 1
Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy
Cantor, J. M. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-42223-7_6 · Cited by 1
Targeting the Lung Cancer Microenvironment: Harnessing Host Responses
Fuster, M. M. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_20 · Cited by 1
Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer
Wrangle, J. M., Paulos, C. M., Smith, T. W., Nishimura, M. I., & Rubinstein, M. P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.002 · Cited by 1
Combination Strategies PD-1/PD-L1 Antagonists
Sznol, M. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000304 · Cited by 1
Adoptive Cell Therapy for Melanoma
Mills, J. K., Darcy, P. K., & Gyorki, D. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-78310-9_34 · Cited by 1
Active Immunotherapy in cancer – Current Status
Khamar, B. M. (2018) · Novel Approaches in Cancer Study · doi:10.31031/nacs.2018.01.000513 · Cited by 1
New Emerging Molecules in Cancer Research Which Hold Promise in Current Era
Bhatia, D. R., Rath, S., & Gupta, S. (2019) · Springer eBooks · doi:10.1007/978-981-32-9816-3_20 · Cited by 1
Stimuli-responsive drug delivery systems for cancer immunotherapy
Ding, Y., & Hu, Q. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824456-2.00014-x · Cited by 1
The First Three Decades of Gene Therapy
Hoh, Y. K. (2023) · The American Biology Teacher · doi:10.1525/abt.2023.85.1.17 · Cited by 1

Authors: Hinrichs, C. S., & Rosenberg, S. A.
Affiliations: National Cancer Institute (US)
Corresponding author: Hinrichs, Christian S.
ORCID: Hinrichs, Christian S.
Rosenberg, Steven A.
Venue: Immunological Reviews
Publisher: Wiley
Published: 2013-12-13
Volume: 257
Issue: 1
Pages: 56-71
ISSN: 0105-2896 (ISSN-L)
1600-065X
DOI: 10.1111/imr.12132
PMC: PMC3920180
OpenAlex: W2150145041
Cited by: 466
References: 137
Citations by year: 2026: 6 · 2025: 20 · 2024: 16 · 2023: 25 · 2022: 36 · 2021: 32 · 2020: 38 · 2019: 39 · 2018: 55 · 2017: 59 · 2016: 56 · 2015: 56 · 2014: 26 · 2013: 1
FWCI: 4.90
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Immunological Reviews (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (ZIABC011478)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: adoptive T cell therapy, tumor-infiltrating lymphocytes, metastatic melanoma, tumor regression, neoantigens, somatic mutations, chimeric antigen receptor, NY-ESO-1, CD19, B-cell malignancies, synovial sarcoma, cancer immunotherapy
MeSH terms: Animals, Antigens, Neoplasm, Humans, Neoplasms, Receptors, Antigen, T-Cell, Protein Engineering, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks